Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.68 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212940 | 0.82 | CYP11B1 (0.64) | CYP11B1CYP11B2AKR1C3PTGS2MAOB | |
| SCHEMBL26669564 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL17723969 | 0.81 | CYP11B1 (1.00) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL19212935 | 0.81 | CYP11B1 (0.64) | CYP11B1CYP11B2CES2CES1KIF11 | |
| SCHEMBL19212996 | 0.79 | CYP11B1 (0.67) | CYP11B1CYP11B2PTGS2MAOB | |
| SCHEMBL7802254 | 0.77 | AKR1C3 (0.62) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL7990329 | 0.75 | PTGS2 (0.57) | CYP11B1CYP11B2AKR1C3PTGS2KIF11 | |
| SCHEMBL863126 | 0.74 | PTGS2 (0.68) | CYP11B1CYP11B2AKR1C3PTGS2KIF11 | |
| SCHEMBL14367111 | 0.72 | CES2 (0.55) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL7506839 | 0.69 | PTGS2 (0.72) | AKR1C3PTGS2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885AKR1C3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.